Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f® + MPL-SE® vaccine to treat canine visceral leishmaniasis

Vaccine

Volumn 26, Issue 12, 2008, Pages 1585-1594

  Miret, Jorge ^a   Nascimento, Evaldo ^a   Sampaio, Weverton ^a   França, João Carlos ^a   Fujiwara, Ricardo Toshio ^a,b   Vale, André ^a   Dias, Edelberto Santos ^b   Vieira, Edvá ^c   Costa, Roberto Teodoro da ^a   Mayrink, Wilson ^a   Neto, Antonio Campos ^d   Reed, Steven ^e  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Fundação Nacional da Saú   (Brazil)

^d FORSYTH INSTITUTE   (United States)

^e INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Canine visceral leishmaniasis; Immunochemotherapy; Leishmania chagasi; Leishmaniasis

Indexed keywords

LEISH 110F; LEISH 110F PLUS MONOPHOSPHORYL LIPID A PLUS SQUALENE; MEGLUMINE ANTIMONATE; MONOPHOSPHORYL LIPID A PLUS SQUALENE; PHOSPHORYL LIPID A; PLACEBO; PLASMA PROTEIN; PROTOZOAL VACCINE; RECOMBINANT VACCINE; SQUALENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DOG; DRUG EFFICACY; DRUG SCREENING; FEMALE; HEMATOLOGICAL PARAMETERS; HUMORAL IMMUNITY; IMMUNOTHERAPY; KIDNEY FUNCTION; LEISHMANIA CHAGASI; LIVER FUNCTION; MALE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; VISCERAL LEISHMANIASIS;

EID: 40049107841     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.01.026     Document Type: Article

References (62)

1. R.J. Slappendel Canine leishmaniasis. A review based on 95 cases in the Netherlands Vet Quarterly 10 1988 1 16
2. F. Mancianti M. Gramiccia L. Gradoni S. Pieri Studies on canine leishmaniasis control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment Trans R Trop Med Hyg 82 1988 566 567
3. P. Denerolle Leishmaniose canine: difficulté du diagnostic et du traitement (125 cas) Prat Méd Chir Animal Comp 31 1996 137 145
4. P. Ciaramella G. Oliva R. De Luna L. Gradoni R. Ambrosio L. Cortese A retrospective clinical study of canine leishmaniasis in 150 dogs naturally infected by Leishmania infantum Vet Rec 141 1997 539 543
5. A.F. Koutinas M.N. Saridomichelakis M. Mylonakis L. Leontides Z. Polizoulou C. Billinis A randomized, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniasis Vet Parasitol 98 2001 247 261
6. A. Blavier S. Keroack P. Denerolle I. Goy-Thollot L. Chabanne J.L. Cadoré Atypical forms of canine leishmaniasis Vet J 162 2001 108 120
7. I. Amusategui A. Sainz F. Rodríguez M.A. Tesouro Distribution and relationship between clinical and histopathological parameters in canine leishmaniasis Eur J Epidemiol 18 2003 147 156
8. Manual of surveillance and control of visceral leishmaniasis. Brasilia: Ministry of Healthy/Brazil; 2003. http://portal.saude.gov.br/portal/arquivos/pdf/manual_leish_visceral2006.pdf .
9. P. Magalhães W. Mayrink C. Costa M.N. Melo M. Dias S.M. Batista Calazar na zona do Rio Doce. Minas Gerais. Resultados de medidas profiláticas Rev Inst Med Trop São Paulo 22 1980 197 202
10. C.B. Palatnik-de-Sousa W.R. dos Santos J.C. França-Silva R.T. da Costa A.B. Reis M. Palatnik Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil Am J Trop Med Hyg 65 5 2001 510 517
11. S.M. Jerónimo M.J. Teixeira A.D. Sousa P. Thielking R.D. Pearson T.G. Evans Natural history of Leishmania ( Leishmania ) chagasi infection in northeastern Brazil: long-term follow-up Clin Infect Dis 30 2000 608 609
12. R. Tesh Control of zoonotic visceral leishmaniasis: its time to change strategies? Am J Trop Med Hyg 52 1995 287 292
13. J.P. Dedet Traitement des leishmanioses: realités et perspectives Méd et Armées 22 1994 73 78
14. F.N. Santos G.P. Borja-Cabrera L.M. Miyashiro J. Grechi A.B. Reis M.A. Moreira Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine Vaccine 25 2007 6176 6190
15. J.L. Guarga J. Moreno J. Lucientes M.J. Gracia M.A. Peribañez J.A. Castillo Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis Vet Immunol Immunopathol 88 2002 13 20
16. W. Mayrink O. Genaro C.A. Costa J.C. França-Silva M.V. Hermeto A. Oliveira-Lima Combined immunotherapy and chemotherapy in canine visceral Leishmaniasis preliminary findings Mem Inst Oswaldo Cruz 87 1992 201
17. M.A. Melo J.C. França-Silva E.O. Azevedo I.M. Tabosa R. Da Costa C.A. Da Costa Clinical trial on the efficacy of the N -methyl glucamine associated to immunotherapy in dogs, experimentally infected with Leishmania ( Leishmania ) chagasi Revue Méd Vét 153 2002 75 84
18. A.B. Neogy Exploitation of parasite-derived antigen in therapeutic success against canine visceral leishmaniasis Vet Parasitol 54 1994 367 373
19. L. Monjour I. Vouldoukis B.W. Ogunkolade C. Hetzel M. Ichen D. Frommel Vaccination and treatment trials against murine leishmaniasis with semi-purified Leishmania antigens Trans R Soc Trop Med Hyg 82 1988 412 415
20. A. Campos-Neto R. Porrozi K. Greeson R.N. Coler J.R. Weeb Y.A.M. Skeiky Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and non-human primate models of human disease Infect Immun 9 2001 4103 4108
21. Y.A.W. Skeiky J.A. Guderian D.R. Benson O. Bacelar E.M. Carvalho M. Kubin A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1 cytokine profile and to produce interleukin12 J Exp Med 181 1995 1527 1537
22. P. Probst Y. Skeiky M. Steeves A. Gervassi K. Grabstein S. Reed A Leishmania protein that modulates interleukin IL-12, IL-10 and tumor necrosis factor production and expression of B7-1 in human monocyte-derived antigen presenting cells Eur J Immunol 27 1997 2634
23. Y.A.W. Skeiky M. Kennedy D. Kaufman M.M. Borges J.A. Guderian J.K. Scholler LeIF: a recombinant Leishmania protein that induces an IL-12 mediated Th1 cytokine profile J Immunol 161 1998 6171 6179
24. M.M. Borges A. Campos-Neto P. Sleath K.H. Grabstein P.J. Morrisey Y.W.A. Skeiky Potent stimulation of the innate immune system by a Leishmania brasiliensis recombinant protein Infect Immun 69 2001 5270 5277
25. R. Badaró I. Lobo A. Munos E.M. Netto F. Modabber A. Campos-Neto Immunotherapy for drug-refractory mucosal leishmaniasis J Infect Dis 194 2006 1151 1159
26. J.R. Weeb D. Kaufman A. Campos-Neto S.G. Reed Molecular cloning of a novel protein antigen of that elicits a potent immune protein antigen of Leishmania major that elicits a potent response in experimentally murine leishmaniasis J Immun 157 1996 5034 5041
27. J.R. Weeb A. Campos-Neto P. Ovendale T.I. Martin E.J. Stromberg J. Badaro Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family Infect Immun 66 1998 3279 3289
28. ® adjuvant Vaccine 20 2002 3293 3303
29. R.T. Fujiwara A.M. Vale J.C. França-Silva R.T. Da Costa J.Q. Da Silva A.B. Reis Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential candidates for canine visceral leishmaniasis Vet Res 36 2005 1 13
30. L. Gradoni V. Foglia Manzillo A. Pagano D. Piantedosi R. De Luna M. Gramiccia Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals Vaccine 23 2005 5245 5251
31. J. Moreno J. Nieto S. Masina C. Cañavate I. Cruz C. Chicharro Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis Vaccine 25 2007 5290 5300
32. E.Y. Rosário O. Genaro J.C. França-Silva R.T. Da Costa W. Mayrink A. Barbosa-Reis Evaluation of enzyme-linked immunosorbent assay using crude Leishmania and recombinant antigens as a diagnostic marker for canine visceral leishmaniasis Mem Inst Oswaldo Cruz 100 2005 197 203
33. N.C. Jain Essentials of veterinary haematology 1993 Lea & Febirger Philadelphia
34. J.J. Kaneko J.W. Harvey M.L. Bruss Clinical biochemistry of domestic animals 1997 Academic Press San Diego p. 932
35. E. Pinelli R. Kellick-Kendrick J. Wagenaar W. Bernardina G. Del Real J. Ruitenberg Cellular and humoral immune response in dogs experimentally infected with Leishmania infantum Infect Immun 62 1994 229 235
36. R.T. Fujiwara A. Loukas S. Mendez A.L. Williamson L.L. Bueno Y. Wang Vaccination with irradiated Ancylostoma caninum third stage larvae induces a Th2 protective response in dogs Vaccine 24 2006 501 509
37. E.M. Michalsky M.F. Rocha A.C.V. Rocha Lima J.C. França-Silva M.Q. Pires F.S. Oliveira Infectivity of seropositive dogs, showing different clinical forms of leishmaniasis, to Lutzomyia longipalpis phlebomine sand flies Vet Parasitol 147 2007 67 76
38. R.A. Fisher Applications of Student's distribution Metron 5 1925 90 104
39. W.H. Kruskall W.A. Wallis Use of ranks in one-criterion variance analysis J Am Stat Assoc 47 1952 583 621
40. J.W. Tukey The problem of multiple comparisons 1953 University of Princeton Princeton, NY
41. D. Collet Modelling survival data in medical research 1994 Chapman & Hall London
42. J.P. Klein J. Moeschberger Survival analysis techniques for censored and truncated data 1997 Springer New York
43. D.R. Cox Analysis of survival data 1984 Chapman & Hall London
44. S.L. Croft G.H. Coombs Leishmaniasis—current chemotherapy and recent advances in the search for novel drugs Trends Parasitol 19 2003 502 508
45. A. Hailu A.M. Musa C. Royce M. Wasunna Visceral leishmaniasis: new health tools are needed PLoS Med 2 2005 590 594
46. S.L. Croft S. Sundar A.H. Fairlamb Drug resistance in leishmaniasis Clin Microbiol Rev 19 2006 111 126
47. W. Mayrink A.C. Botelho P.A. Magalhães S.M. Batista A.O. Lima O. Genaro Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment Rev Soc Bras Med Trop 39 2006 14 21
48. B.L. Herwaldt J.D. Berman Recommendations for treating leishmaniosis with sodium stibogluconate (Pentostan) and review of pertinent clinical studies Am J Trop Med Hyg 46 1992 296 306
49. I. Amusategui F. Rodríguez M.A. Tesouro Tratamiento de la leishmaniosis canina, Parte I Med Vet 12 1995 289 298
50. J. Alvar R. Molina M. San Andrés M. Tesouro J. Nieto M. Vitutia Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy Ann Trop Med Parasitol 88 1994 371 378
51. G. Oliva L. Gradoni L. Cortese S. Orsini P. Ciaramella A. Scalone Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone, or in combination in canine leishmaniasis Ann Trop Med Parasitol 92 1998 165 171
52. A. Rhalem H. Sahibi S. Lasri C.L. Jaffe Analysis of immune responses in dogs with canine visceral leishmaniasis before, and after, drug treatment Vet Immunol Immunopathol 71 1999 69 76
53. L. Gradoni M. Maroli M. Gramiccia F. Mancianti Leishmania infantum infection rates in Phlebotomus perniciosus fed in naturally infected dogs under antimonial treatment Med Vet Entomol 1 1987 339 342
54. S. Pasa S. Ozensoy-Toz H. Vodyvoda Y. Ozbel Clinical and serological follow-up in dogs with visceral leishmaniosis treated with allopurinol and sodium stibogluconate Vet Parasitol 128 2005 243 249
55. S.G. Reed P. Scott T-cell and cytokine responses in leishmaniasis Curr Opin Immunol 5 1993 524 531
56. E.M. Carvalho R. Badaró S.G. Reed T.C. Jones W.D. Johnson Absence of gamma interferon and interleukin 2 during active visceral leishmaniasis J Clin Invest 76 1985 2006 2009
57. R. Badaró E.M. Carvalho M.G. Orge Imunidade humoral e celular em indivíduos curados de leishmaniose visceral Rev Soc Bras Med Trop 18 1985 77 83
58. J. Moreno J. Nieto C. Chamizo F. González F. Blanco D.C. Barrer The immune response and PBMC subsets in canine visceral leishmaniasis before, and after chemotherapy Vet Immunol Immunopathol 71 1999 181 195
59. I. Ramos A. Alonso J.M. Marcen A. Peris J.A. Castillo M. Colmenares Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response Vaccine 2007 [November 29, Epub ahead of print]
60. G.P. Borja-Cabrera N.N. Correia Pontes V.O. da Silva E. Paraguai de Souza W.R. Santos E.M. Gomes Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante RN) Vaccine 20 2002 3288 3384
61. G.P. Borja-Cabrera A. Cruz Mendes E. Paraguai de Souza L.Y. Hashimoto Okada F.A. de A Trivellato J.K. Kawasaki Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine Vaccine 22 2004 2234 2243
62. J.T. Ulrich K.R. Myers Monophosphoryl A as an adjuvant M.F. Powel M.J. Newman Vaccine design: the subunit and adjuvant approach 1995 Plenum Press New York 495